The FDA Ordered GLP-1 Vision-Loss Warnings For Some Products. Shares of Eli Lilly and Novo Nordisk Were Unfazed.
Eli Lilly and Novo Nordisk shares climbed Monday, outpacing the broader health care sector even as U.S. regulators ordered new warnings in some its biggest sellers about a rare…
DO
By Daniel Okafor · Regulatory Correspondent
Nov 10 07:41 ETSource: International Business Times
From the source
Read at ibtimes.comThe FDA Ordered GLP-1 Vision-Loss Warnings For Some Products. Shares of Eli Lilly and Novo Nordisk Were Unfazed.
Eli Lilly and Novo Nordisk shares climbed Monday, outpacing the broader health care sector even as U.S. regulators ordered new warnings in some its biggest sellers about a rare eye condition that can cause sudden, permanent vision loss.
